Systematic Review and Meta-analysis of Deaths Attributable to Antimicrobial Resistance, Latin America.

Argentina Brazil Caribbean region Colombia Latin America antimicrobial resistance bacteria lethality methicillin-resistant Staphylococcus aureus mortality

Journal

Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155

Informations de publication

Date de publication:
11 2023
Historique:
medline: 26 10 2023
pubmed: 25 10 2023
entrez: 25 10 2023
Statut: ppublish

Résumé

Antimicrobial resistance is a pressing global health concern, leading to 4.95 million deaths in 2019. We conducted a systematic review and meta-analysis to assess the lethality attributed to infections caused by multidrug-resistant organisms (MDROs) in Latin America and the Caribbean. A comprehensive search of major databases retrieved relevant studies from 2000-2022. We included 54 observational studies, primarily from Brazil, Argentina, and Colombia. The most commonly studied organism was methicillin-resistant Staphylococcus aureus. The overall unadjusted case fatality rate related to MDROs was 45.0%; higher adjusted lethality was observed in persons infected with MDROs than in those infected with other pathogens (adjusted odds ratio 1.93, 95% CI 1.58-2.37). A higher lethality rate was seen in patients who did not receive appropriate empirical treatment (odds ratio 2.27, 95% CI 1.44-3.56). These findings underscore the increased lethality associated with antimicrobial resistance in Latin America and the Caribbean.

Identifiants

pubmed: 37877573
doi: 10.3201/eid2911.230753
pmc: PMC10617342
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Meta-Analysis Systematic Review Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2335-2344

Références

Intensive Care Med. 2019 Dec;45(12):1703-1717
pubmed: 31664501
Mem Inst Oswaldo Cruz. 2006 Jun;101(4):415-21
pubmed: 16951813
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
J Hosp Infect. 2006 Jul;63(3):330-6
pubmed: 16713018
Syst Rev. 2021 Mar 29;10(1):89
pubmed: 33781348
J Antimicrob Chemother. 2010 Dec;65(12):2658-65
pubmed: 20947620
Clin Infect Dis. 2005 Aug 1;41(3):327-33
pubmed: 16007529
J Antimicrob Chemother. 2022 Feb 23;77(3):807-815
pubmed: 34957520
Clin Infect Dis. 2020 Dec 3;71(9):2459-2468
pubmed: 32358954
Antimicrob Agents Chemother. 2010 Oct;54(10):4085-91
pubmed: 20660675
Antimicrob Resist Infect Control. 2018 Apr 25;7:58
pubmed: 29713465
Clin Infect Dis. 2003 Jan 1;36(1):53-9
pubmed: 12491202
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Environ Sci Eur. 2022;34(1):21
pubmed: 35281760
Evid Based Ment Health. 2019 Nov;22(4):153-160
pubmed: 31563865
J Antimicrob Chemother. 2006 Aug;58(2):387-92
pubmed: 16751638
Medicine (Baltimore). 2019 Jun;98(23):e15801
pubmed: 31169679
Clin Microbiol Infect. 2014 May;20(5):416-23
pubmed: 24131374
Clin Microbiol Infect. 2020 Dec;26(12):1622-1629
pubmed: 32711058
Clin Microbiol Infect. 2014 Feb;20(2):174-80
pubmed: 23668595
Infect Control Hosp Epidemiol. 2007 Mar;28(3):273-9
pubmed: 17326017
J Infect Public Health. 2021 May;14(5):555-560
pubmed: 33848884
Support Care Cancer. 2018 Dec;26(12):4057-4065
pubmed: 29948391
Rev Panam Salud Publica. 2012 Nov;32(5):343-50
pubmed: 23338691
J Antimicrob Chemother. 2018 Jan 01;73(1):212-222
pubmed: 29045648
J Infect. 2013 May;66(5):401-14
pubmed: 23142195
Emerg Infect Dis. 2022 Nov;28(11):1-8
pubmed: 36286547
Infect Control Hosp Epidemiol. 2009 Dec;30(12):1180-5
pubmed: 19860564
Arch Med Res. 2002 May-Jun;33(3):290-4
pubmed: 12031636
PLoS Med. 2016 Nov 29;13(11):e1002184
pubmed: 27898664
Braz J Infect Dis. 2002 Dec;6(6):288-97
pubmed: 12585972
J Med Microbiol. 2021 Jan;70(1):
pubmed: 33258755
Stat Med. 2003 Sep 15;22(17):2693-710
pubmed: 12939780
J Infect. 2009 Feb;58(2):131-7
pubmed: 19211147
J Antimicrob Chemother. 2007 Nov;60(5):913-20
pubmed: 17848376
J Infect. 2018 May;76(5):438-448
pubmed: 29477802
BMC Infect Dis. 2020 Mar 27;20(1):250
pubmed: 32220233
Rev Soc Bras Med Trop. 2018 Jul-Aug;51(4):415-420
pubmed: 30133622
J Antimicrob Chemother. 2012 Jun;67(6):1311-20
pubmed: 22396430
Int J Infect Dis. 2018 Jun;71:59-64
pubmed: 29649549
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH